Rephonic
Artwork for The Top Line
Artificial Intelligence
FDA
Biopharma
Clinical Trials
Pharmaceutical Industry
Oncology
Eli Lilly
Mergers and Acquisitions
Novo Nordisk
Drug Development
Drug Pricing
Biotechnology
Pfizer
Cell Therapy
Biotech
Gene Therapy
Patient Engagement
Alzheimer's Disease
Lung Cancer
Companion Diagnostics

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.

PublishesTwice weeklyEpisodes100Founded3 years ago
Number of ListenersCategories
Business NewsNews

Listen to this Podcast

Artwork for The Top Line

Latest Episodes

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.

In this week’s episode ... more

The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer medicines to protecting vaccine science, improving health literacy and expandin... more

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthcare agencies reach audiences.

In this week’s episode of “The Top Line,” Fierce’s Ben Adams and Zoey... more

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1 battle between Novo Nordisk and Eli Lilly and new leadership at Sarepta and... more

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
WSJ's Take On the Week
WSJ's Take On the WeekThe Wall Street Journal

Recent Guests

Dan Paterson
Chief Executive Officer of Verastem Oncology
Verastem Oncology
Episode: The future of RAS inhibitors
Jonathan Pachter
Chief Scientific Officer of Verastem Oncology
Verastem Oncology
Episode: The future of RAS inhibitors
Jay Bradner
EVP of R&D, AI and Data at Amgen
Amgen
Episode: MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check
Suzy Tapponi
Head of Corporate Affairs at Amgen
Amgen
Episode: MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check
Rachel Stoll
Managing Partner of Growth and Innovation at Princeton10
Princeton10
Episode: How consumerization is reshaping pharma marketing (Sponsored)
Kevin Nalty
Vice President Strategy at Princeton10
Princeton10
Episode: How consumerization is reshaping pharma marketing (Sponsored)
Andy Deubler
Chief Business and Administrative Officer at Regeneron Genetics Center
Regeneron Genetics Center
Episode: A genomics library for the AI era
Kirti Prakash
Principal at ZS, focused on patient strategy and services
ZS
Episode: The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)
Asheesh Shukla
Principal at ZS, leads global patient strategy and services; leads ZS's Zaden platform
ZS
Episode: The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)

Hosts

Ayla Ellison
Host of The Top Line
Stephanie Butler
Host of The Top Line

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#41
United States/News/Business News
Apple Podcasts
#82
Canada/News/Business News
Apple Podcasts
#84
United Kingdom/News/Business News
Apple Podcasts
#23
Australia/News/Business News
Apple Podcasts
#28
Italy/News/Business News
Apple Podcasts
#56
Germany/News/Business News
Apple Podcasts
#158
France/News/Business News
Apple Podcasts
#16
Israel/News/Business News
Apple Podcasts
#27
South Korea/News/Business News
Apple Podcasts
#29
China/News/Business News
Apple Podcasts
#29
Hong Kong/News/Business News
Apple Podcasts
#35
Norway/News/Business News
Apple Podcasts
#35
Denmark/News/Business News
Apple Podcasts
#37
Switzerland/News/Business News
Apple Podcasts
#41
Netherlands/News/Business News
Apple Podcasts
#45
Austria/News/Business News
Apple Podcasts
#51
Russia/News/Business News
Apple Podcasts
#52
Saudi Arabia/News/Business News
Apple Podcasts
#55
Ireland/News/Business News
Apple Podcasts
#62
Taiwan/News/Business News
Apple Podcasts
#75
Sweden/News/Business News
Apple Podcasts
#75
South Africa/News/Business News
Apple Podcasts
#82
Singapore/News/Business News
Apple Podcasts
#88
Belgium/News/Business News
Apple Podcasts
#95
Poland/News/Business News
Apple Podcasts
#105
Japan/News/Business News
Apple Podcasts
#106
Finland/News/Business News
Apple Podcasts
#124
New Zealand/News/Business News
Apple Podcasts
#141
Mexico/News/Business News
Apple Podcasts
#158
Spain/News/Business News
Apple Podcasts
#178
India/News/Business News
Apple Podcasts
#179
Brazil/News/Business News
Apple Podcasts
#208
United Arab Emirates/News/Business News
Apple Podcasts
#210
Hong Kong/News
Apple Podcasts
#238
China/News

Talking Points

Recent interactions between the hosts and their guests.

The future of RAS inhibitors
Q: What are the near-term data milestones and how might resistance evolve?
They anticipate October data across several cancers, with durability and resistance mechanisms likely to be addressed by combining with other agents and potentially sequencing therapies based on emerging resistance mutations.
The future of RAS inhibitors
Q: What is the role of GenFleet in advancing VS7375 and other targets?
GenFleet provides translational research and collaboration to identify and develop additional targets in the RAS pathway, enhancing the potential to treat RAS-driven tumors with a multi-target approach.
The future of RAS inhibitors
Q: How does Verastem differentiate its approach to RAS inhibition from competitors?
The team emphasizes a G12D-selective inhibitor with dual on-off potency, long residence time, and favorable pharmacokinetics, aiming for high efficacy with tolerability and a strategy of combining with other agents to broaden impact.
The future of RAS inhibitors
Q: What does the Revolution Medicines approval mean for patients and the broader field of oncology?
Dan and John suggest the approval is a significant leap forward, proving the RAS-targeting approach works and signaling potential for expanding RAS inhibition to other indications and earlier lines of therapy.
MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check
Q: How is AI changing agency workflows without replacing human creativity?
Ayla and Ben discuss AI as a supporting tool that enhances efficiency, data analysis, and risk flagging (e.g., OPDP integrations), while underscoring that humans remain responsible for strategy and creative execution.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The Top Line

What is The Top Line about and what kind of topics does it cover?

This show concentrates on biopharma, medtech, and healthcare business trends, blending industry news, deals, and science with strategic takeaways for practitioners. Episodes frequently explore data, AI, regulatory designations, clinical development, and market movements, often featuring sponsor-led conversations or editor analysis that translates complex topics into practical guidance for sponsors, researchers, and executives. Notable strengths include hands-on frameworks for modernizing operations, data governance, and patient-centric engagement, plus a track record of bringing together reporters and industry leaders to unpack high-stakes topics from FDA designations to M&A dynamics. Potential listeners who want concise, business-focused i... more

Where can I find podcast stats for The Top Line?

Rephonic provides a wide range of podcast stats for The Top Line. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The Top Line and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The Top Line get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for The Top Line, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The Top Line?

Rephonic provides comprehensive predictive audience data for The Top Line, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The Top Line have?

To see how many followers or subscribers The Top Line has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The Top Line?

These podcasts share a similar audience with The Top Line:

1. The Readout Loud
2. BioCentury This Week
3. Biotech Hangout
4. WSJ's Take On the Week
5. The Indicator from Planet Money

How many episodes of The Top Line are there?

The Top Line launched 3 years ago and published 100 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The Top Line?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The Top Line?

Rephonic pulls ratings and reviews for The Top Line from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The Top Line?

Rephonic provides full transcripts for episodes of The Top Line. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The Top Line?

Recent guests on The Top Line include:

1. Dan Paterson
2. Jonathan Pachter
3. Jay Bradner
4. Suzy Tapponi
5. Rachel Stoll
6. Kevin Nalty
7. Andy Deubler
8. Kirti Prakash

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days